Skip to main content

ketorolac

Generic: KETOROLAC TROMETHAMINE·Brand: ACULAR, ACULAR LS, ACULAR PRESERVATIVE FREE, ACUVAIL, Acular, Acuvail, KETOROLAC TROMETHAMINE, Omidria, SPRIX, Sprix, TORADOL

ketorolac: developed by 1 company · 9 clinical trials tracked · 1 FDA decision.

ketorolac evidence translation

What we can confirm

1 FDA record · 9 tracked trials

What it means

Source-backed records connect ketorolac to ABBV; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could ketorolac → ABBV affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 4 study sponsors
Development Pipeline (1)
CompanyPhase
AbbVie Inc. (ABBV)Approved
Clinical Trials (9)

Postoperative Pain Outcomes After Use of Bupivacaine-Meloxicam Extended-Release Solution in Robot Assisted Total Knee Arthroplasty: A Prospective Study

NCT07430085·Phase 4·GHRS
Not yet recruiting

Primary endpoint: Amount of opioid medications used (measured in morphine milligrams equivalents)

InterventionalRandomizeddouble150 targetStarted 2026-07Completion 2028-02Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Optimizing Pain Treatment in Children On Mechanical Ventilation

NCT06994442·Phase 3
Recruiting

Primary endpoint: Acute Pain Episodes

InterventionalRandomizedquadruple644 targetStarted 2025-12Completion 2029-0816 sites · United StatesWeill Medical College of Cornell University

Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial

NCT07092566·Phase 3
Recruiting

Primary endpoint: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) pain intensity scores through 7 days (168 hours) for participants receiving Exparel vs. R.E.C.K.

InterventionalRandomizedopen170 targetStarted 2025-11Completion 2027-101 site · United StatesWake Forest University Health Sciences

Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients

NCT06201676·Phase 4
Recruiting

Primary endpoint: Chronic Opioid Use

InterventionalRandomizedopen458 targetStarted 2025-02Completion 2027-082 sites · United StatesMassachusetts General Hospital

Efficacy of Nasal Migraine Cocktail Used In Pediatric Emergency Department: A Clinical Trial

NCT06083571·Phase 2
Terminated

Primary endpoint: Change from baseline in pain on the 10 point Faces Pain Scale-Revised in 2 hours

InterventionalRandomizedquadruple41 targetStarted 2024-01Completion 2025-121 site · United StatesWashington University School of Medicine

NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis: A Randomized, Controlled Trial

NCT05992883·Phase 3·VALN
Recruiting

Primary endpoint: Visual Analogue Scale (VAS) of Pain

InterventionalRandomizeddouble240 targetStarted 2023-07Completion 2026-121 site · United StatesMayo Clinic

Multimodal Nonopioid Pain Protocol Following Shoulder Arthroplasty Surgery

NCT05488847·Phase 4·FLNA
Active, not recruiting

Primary endpoint: Pain Levels

InterventionalRandomizedsingle83 targetStarted 2022-06Completion 2026-091 site · United StatesHenry Ford Health System

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy (INSPIRE) Study

NCT04505566·Phase 1

Primary endpoint: PGE2 level during Diabetic Retinopathy progression

InterventionalRandomizeddouble164 targetStarted 2020-11Completion 2026-051 site · United StatesStephen J. Kim, MD

A Phase 2, Open-Label Study of HTX 011 in a Multimodal Analgesic Regimen for Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy

NCT03695367·Phase 2·HRTX
Completed

Primary endpoint: Percentage of Subjects Receiving no Opioid Rescue

Interventionalopen63 enrolledStarted 2018-10Completion 2018-125 sites · United StatesHeron Therapeutics
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ACUVAIL ® is indicated for the treatment of pain and inflammation following cataract surgery. ACUVAIL is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery. ( 1 )(ABBV)FDA ↗
NDA022427Type 5 - New Formulation or New ManufacturerStandardOphthalmicSolution/Drops

Frequently asked questions

Who is developing ketorolac?

ketorolac is being developed by AbbVie Inc..

How many clinical trials involve ketorolac?

BioSniper tracks 9 clinical trials involving ketorolac.

What is ketorolac's latest FDA decision?

The most recent tracked FDA decision for ketorolac is Approval for 1 INDICATIONS AND USAGE ACUVAIL ® is indicated for the treatment of pain and inflammation following cataract surgery. ACUVAIL is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery. ( 1 ), dated July 22, 2009.